Kay Noonan

411 total citations
10 papers, 288 citations indexed

About

Kay Noonan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Kay Noonan has authored 10 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in Kay Noonan's work include BRCA gene mutations in cancer (4 papers), PARP inhibition in cancer therapy (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Kay Noonan is often cited by papers focused on BRCA gene mutations in cancer (4 papers), PARP inhibition in cancer therapy (4 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Kay Noonan collaborates with scholars based in United States, Italy and South Korea. Kay Noonan's co-authors include Philippe Schafhausen, Eric Leip, H. Jean Khoury, Jörge E. Cortes, Tim H. Brümmendorf, Hagop M. Kantarjian, Dong‐Wook Kim, Carlo Gambacorti‐Passerini, Jeff H. Lipton and Tony Mok and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Kay Noonan

10 papers receiving 283 citations

Peers

Countries citing papers authored by Kay Noonan

Since Specialization

Citations

This map shows the geographic impact of Kay Noonan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kay Noonan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kay Noonan more than expected).

Fields of papers citing papers by Kay Noonan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kay Noonan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kay Noonan. The network helps show where Kay Noonan may publish in the future.

Co-authorship network of co-authors of Kay Noonan

This figure shows the co-authorship network connecting the top 25 collaborators of Kay Noonan. A scholar is included among the top collaborators of Kay Noonan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kay Noonan. Kay Noonan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status 2024 ·Breast Cancer ·Melinda L. Telli, Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones, Jay Andersen, Lida A. Mina, (unknown), Michael Danso, Yuan Yuan, W. Fraser Symmans, Julia F. Hopkins, Lee A. Albacker, Antonello Abbattista, Kay Noonan, Marielena Mata, Alexander Laird, Joanne L. Blum	8
2	Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study 2023 ·The Oncologist ·Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones, Jay Andersen, Joanne L. Blum, Lida A. Mina, (unknown), Michael Danso, Yuan Yuan, Antonello Abbattista, Kay Noonan, (unknown), Jayeta Chakrabarti, Akos Czibere, W. Fraser Symmans, Melinda L. Telli	21
3	Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study. 2021 ·Journal of Clinical Oncology ·Melinda L. Telli, Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones, Jay Andersen, Lida A. Mina, (unknown), Michael Danso, Yuan Yuan, W. Fraser Symmans, Antonello Abbattista, Kay Noonan, Marielena Mata, Douglas Laird, Joanne L. Blum	3
4	Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. 2021 ·Journal of Clinical Oncology ·Jennifer K. Litton, J. Thaddeus Beck, Jason M. Jones, Jay Andersen, Joanne L. Blum, Lida A. Mina, (unknown), Michael Danso, Yuan Yuan, Antonello Abbattista, Kay Noonan, Jayeta Chakrabarti, Akos Czibere, W. Fraser Symmans, Melinda L. Telli	29
5	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations 2020 ·Drugs ·Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, (unknown), Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, (unknown), Keith D. Wilner, Yi‐Long Wu	84
6	Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations 2019 ·Annals of Oncology ·Tony Mok, Ying Cheng, Xiangdong Zhou, (unknown), Kazuhiko Nakagawa, Seiji Niho, R. Linke, Rafael Rosell, J. Corral, M.R. Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, Keith D. Wilner, Yi‐Long Wu	14
7	Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis 2019 ·Future Oncology ·Qing Zhou, Yi‐Long Wu, J. Corral, Kazuhiko Nakagawa, Edward B. Garon, Eric Sbar, Tao Wang, Rickard Sandin, Kay Noonan, Diana Gernhardt, Tony Mok	12
8	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study 2018 ·Haematologica ·Carlo Gambacorti‐Passerini, Jörge E. Cortes, Jeff H. Lipton, Hagop M. Kantarjian, Dong‐Wook Kim, Philippe Schafhausen, Rocco J. Crescenzo, Nathalie Bardy‐Bouxin, Mark Shapiro, Kay Noonan, Eric Leip, (unknown), Tim H. Brümmendorf, H. Jean Khoury	44
9	Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib 2016 ·American Journal of Hematology ·Jörge E. Cortes, H. Jean Khoury, Hagop M. Kantarjian, Jeff H. Lipton, Dong‐Wook Kim, Philippe Schafhausen, Ewa Matczak, Eric Leip, Kay Noonan, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini	68
10	Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study 2014 ·Blood ·Carlo Gambacorti‐Passerini, H. Jean Khoury, Hagop M. Kantarjian, Jeffrey H. Lipton, Dong‐Wook Kim, Philippe Schafhausen, Ewa Matczak, Eric Leip, Kay Noonan, Tim H. Brümmendorf, Jörge E. Cortes	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact